Review



osteoassay human bone plates  (Lonza)


Bioz Verified Symbol Lonza is a verified supplier
Bioz Manufacturer Symbol Lonza manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Lonza osteoassay human bone plates
    Osteoassay Human Bone Plates, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteoassay+human+bone+plates/osteoassay+bone+plates/us12090249-454-26-30
    Average 90 stars, based on 1 article reviews
    osteoassay human bone plates - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Implant and coating to reduce osteolysis
    Article Snippet: This may be further validated using human primary monocyte osteoclast progenitors (e.g. from Lonza (2T-110)).

    Article Title: Implant and coating to reduce osteolysis
    Article Snippet: Human primary monocyte osteoclast progenitors may be purchased from Lonza (2T-110).

    Article Title: The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
    Article Snippet: Regulation of osteoclast differentiation and function is a central element in bone homeostasis.. While the role of soluble factors, such as cytokines, hormones and growth factors, in controlling osteoclast differentiation has been intensively characterized, the function of surface receptors is less well understood.. Sialic acid-binding immunoglobulin-like lectin (Siglec)-9 and its murine homolog Siglec-E are sialic acid-recognizing inhibitory receptors from the CD33-related Siglec-family and mainly expressed on myeloid cells.

    Cell Culture:

    Article Title: Implant and coating to reduce osteolysis
    Article Snippet: This may be further validated using human primary monocyte osteoclast progenitors (e.g. from Lonza (2T-110)). .. In this system, co-treatment with M-CSF/CSF1 (33 ng/mL) and RANKL (66 ng/ml) is required for 7-14 days to induce osteoclast differentiation of progenitors when cultured on OsteoAssay Human Bone Plates (Lonza PA-1000) or bone slices (IDS/Immunodiagnostics DT-1BON1000-96). ..

    Article Title: Implant and coating to reduce osteolysis
    Article Snippet: Human primary monocyte osteoclast progenitors may be purchased from Lonza (2T-110). .. In this system, co-treatment with M-CSF/CSF1 (33 ng/mL) and RANKL (66 ng/ml) is required for 7-14 days to induce osteoclast differentiation of progenitors when cultured on OsteoAssay Human Bone Plates (Lonza PA-1000)55 or bone/dentine slices56 (IDS/Immunodiagnostics DT-1BON1000-96). ..

    Article Title: Implant and coating to reduce osteolysis
    Article Snippet: This may be further validated using human primary monocyte osteoclast progenitors (e.g. from Lonza (2T-110)). .. In this system, co-treatment with M-CSF/CSF1 (33 ng/mL) and RANKL (66 ng/ml) is required for 7-14 days to induce osteoclast differentiation of progenitors when cultured on OsteoAssay Human Bone Plates (Lonza PA-1000) or bone slices (IDS/Immunodiagnostics DT-1BON1000-96). ..



    Similar Products

    osteoassay human bone plates  (Lonza)
    90
    Lonza osteoassay human bone plates
    Osteoassay Human Bone Plates, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteoassay+human+bone+plates/osteoassay+bone+plates/us12090249-454-26-30
    Average 90 stars, based on 1 article reviews
    osteoassay human bone plates - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    osteoassay human bone plate  (Lonza)
    90
    Lonza osteoassay human bone plate
    Osteoassay Human Bone Plate, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteoassay+human+bone+plates/osteoassay+bone+plates/pm36821545-91-18-22
    Average 90 stars, based on 1 article reviews
    osteoassay human bone plate - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    osteoassay™ human bone plate  (Lonza)
    90
    Lonza osteoassay™ human bone plate
    (A-D) BMMs were treated with PP i (100-1000) μM then differentiated with RANK-L (35 ng) over human <t>OsteoAssay</t> bone chips and examined for TRAP. (A) Microscopic images show larger TRAP+ osteoclasts (arrows) and less bone chips (asterisk) in PP i -treated BMMs, compared to control. (B) TRAP activity of differentiated osteoclasts are significantly up in PP i -treated BMMs. Parameters of osteoclast function that include; Ca 2+ (C) , and CTX-1 (D) in the CM are increased in PP i -treated BMMs, compared to control. (E-H) BMMs were treated with PP i (100-1000) μM then differentiated with RANKL (35 ng) over OsteoAssay discs. (E) Microscopic images of von kossa stained discs, after removal of osteoclasts, show increased number and size of resorption pits in PP i -treated BMMs. Parameters of bone resorptions that include; number of resorption pits (N. pits) (F) , total resorption area (Tt. Ar) (G) , and average pit size per osteoclast (pit Ar) are higher in PP i -treated BMMs, compared to control. Experiments were repeated at least 3 times and showed similar results. N= 6 per group. N= 6 per group. The Mean value is represented in all graphs + SEM. *, p < 0.05; **, p < 0.01. Scale bars , 200 μm.
    Osteoassay™ Human Bone Plate, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteoassay+human+bone+plates/osteoassay+bone+plates/bio_rxiv__2020__10__01__321976-114-8-12
    Average 90 stars, based on 1 article reviews
    osteoassay™ human bone plate - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A-D) BMMs were treated with PP i (100-1000) μM then differentiated with RANK-L (35 ng) over human OsteoAssay bone chips and examined for TRAP. (A) Microscopic images show larger TRAP+ osteoclasts (arrows) and less bone chips (asterisk) in PP i -treated BMMs, compared to control. (B) TRAP activity of differentiated osteoclasts are significantly up in PP i -treated BMMs. Parameters of osteoclast function that include; Ca 2+ (C) , and CTX-1 (D) in the CM are increased in PP i -treated BMMs, compared to control. (E-H) BMMs were treated with PP i (100-1000) μM then differentiated with RANKL (35 ng) over OsteoAssay discs. (E) Microscopic images of von kossa stained discs, after removal of osteoclasts, show increased number and size of resorption pits in PP i -treated BMMs. Parameters of bone resorptions that include; number of resorption pits (N. pits) (F) , total resorption area (Tt. Ar) (G) , and average pit size per osteoclast (pit Ar) are higher in PP i -treated BMMs, compared to control. Experiments were repeated at least 3 times and showed similar results. N= 6 per group. N= 6 per group. The Mean value is represented in all graphs + SEM. *, p < 0.05; **, p < 0.01. Scale bars , 200 μm.

    Journal: bioRxiv

    Article Title: Inorganic Pyrophosphate Promotes Osteoclastogenic Commitment and Survival of Bone Marrow Derived Monocytes mediated by Egr-1 up-regulation and MITF phosphorylation

    doi: 10.1101/2020.10.01.321976

    Figure Lengend Snippet: (A-D) BMMs were treated with PP i (100-1000) μM then differentiated with RANK-L (35 ng) over human OsteoAssay bone chips and examined for TRAP. (A) Microscopic images show larger TRAP+ osteoclasts (arrows) and less bone chips (asterisk) in PP i -treated BMMs, compared to control. (B) TRAP activity of differentiated osteoclasts are significantly up in PP i -treated BMMs. Parameters of osteoclast function that include; Ca 2+ (C) , and CTX-1 (D) in the CM are increased in PP i -treated BMMs, compared to control. (E-H) BMMs were treated with PP i (100-1000) μM then differentiated with RANKL (35 ng) over OsteoAssay discs. (E) Microscopic images of von kossa stained discs, after removal of osteoclasts, show increased number and size of resorption pits in PP i -treated BMMs. Parameters of bone resorptions that include; number of resorption pits (N. pits) (F) , total resorption area (Tt. Ar) (G) , and average pit size per osteoclast (pit Ar) are higher in PP i -treated BMMs, compared to control. Experiments were repeated at least 3 times and showed similar results. N= 6 per group. N= 6 per group. The Mean value is represented in all graphs + SEM. *, p < 0.05; **, p < 0.01. Scale bars , 200 μm.

    Article Snippet: BMMs were cultured for 48 hours in the OsteoAssay™ Human Bone Plate (Lonza, Walkersville, MD) coated with a thin layer of adherent human bone particles in complete medium containing 25 ng/ml MCSF and PP i (100-1000 μM).

    Techniques: Activity Assay, Staining